Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27389072 | 1.00 | GPR139 (0.56) | GPR139FOLH1NAALAD2CA2GAA | |
| SCHEMBL6256233 | 0.89 | CA2 (0.54) | GPR139FOLH1CA2CA1SLC6A9 | |
| SCHEMBL27476362 | 0.85 | GPR139 (0.58) | GPR139CA2GAACA1SLC6A9 | |
| SCHEMBL27476363 | 0.85 | GPR139 (0.58) | GPR139CA2GAACA1SLC6A9 | |
| SCHEMBL698067 | 0.85 | CA2 (0.67) | FOLH1NAALAD2CA2GAACA1 | |
| SCHEMBL97498 | 0.85 | CA2 (0.67) | FOLH1NAALAD2CA2GAACA1 | |
| SCHEMBL715646 | 0.85 | CA2 (0.67) | FOLH1NAALAD2CA2GAACA1 | |
| Ammonia Solution, Strong SCHEMBL28375957 | 0.83 | CA2 (0.65) | FOLH1NAALAD2CA2GAACA1 | |
| SCHEMBL4618531 | 0.83 | CA2 (0.65) | FOLH1NAALAD2CA2GAACA1 | |
| SCHEMBL28286177 | 0.83 | CA2 (0.65) | FOLH1NAALAD2CA2GAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0896626-B1 | MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-20060026695-A1 | Transgenically produced fusion proteins | EDGE MICHAEL D | 2006-02-02 | — | — | US | disclosed |
| US-6903203-B2 | Monoclonal antibody to CEA, conjugates comprising said antibody and their therapeutic use | ASTRAZENECA UK LTD. (GB) | 2005-06-07 | — | — | US | disclosed |
| US-20040117863-A1 | Transgenically produced fusion proteins | EDGE MICHAEL D (GB) | 2004-06-17 | — | — | US | disclosed |
| CN-1095677-C | Compound (I) | ZENECA LTD (GB) | 2002-12-11 | — | — | CN | disclosed |
| WO-2001019846-A9 | TRANSGENICALLY PRODUCED FUSION PROTEINS | GENZYME TRANSGENICS CORP (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020142359-A1 | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system | ASTRAZENECA UK LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| US-6436691-B1 | CONJUGATE WHICH IS SUBSTANTIALLY NON-IMMUNOGENIC IN HUMANS COMPRISING TARGETING MOIETY CAPABLE OF BINDING WITH TUMOR ASSOCIATED ANTIGEN LINKED TO MUTATED FORM OF CARBOXYPEPTIDASE B ENZYME CAPABLE OF CONVERTING PRODRUG INTO ANTICANCER DRUG | ZENECA LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| EP-1220864-A1 | TRANSGENICALLY PRODUCED FUSION PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6277599-B1 | MONOCLONAL ANTIBOBY FOR THE PREFERENTIAL KILLING OF TUMORS; FOR DIAGNOSIS OF CANCER; FOR THE TREATMENT OF CANCER | ZENECA LIMITED (GB) | 2001-08-21 | — | — | US | disclosed |
| CN-1217750-A | Monoclonal antibody to CEA, Conjugates comprising said antibody, and their therapeutic use in ADEPT system | ZENECA LTD (GB) | 1999-05-26 | — | — | CN | disclosed |
| EP-0896626-A1 | MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM | ZENECA LIMITED (GB) | 1999-02-17 | — | — | EP | disclosed |
| CN-1193278-A | Chemical compounds | ZENECA LTD (GB) | 1998-09-16 | — | — | CN | disclosed |
| WO-1998035988-A1 | PROTEINS | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| EP-0844885-A2 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| CN-1171054-A | Compound (I) | ZENECA LTD (GB) | 1998-01-21 | — | — | CN | disclosed |
| EP-0806964-A1 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997042329-A1 | MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997007769-A2 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996020011-A1 | CHEMICAL COMPOUNDS | ZENECA LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |